Results from 327 women demonstrated: Significant increases in satisfying sexual events compared to placebo at 1.25 mg and 1.75 mg doses Improved Female Sexual Function Index total scores (mean improvement of 3.6 points vs 1.9 for placebo) Reduced sexual distress as measured by Female Sexual Distress Scale scores Dose-dependent response with optimal effects at 1.75 mg Two Phase 3 trials (RECONNECT studies) enrolled over 1,200 premenopausal women with acquired, generalized HSDD and confirmed efficacy at the 1.75 mg dose administered subcutaneously at least 45 minutes before anticipated sexual activity
It remains the preferred GHS pairing for a DAC-modified GHRH analogue in research models
Heres how to do it: Pro Tip: Before bed, try a little petroleum jelly or ghee for an overnight moisture boost
Patient, knowledgeable, and willing to listen to your individual struggles to tailor a plan that fits YOU
Tirzepatide is technically the combination of two different drugs: a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Because of this, Tirzepatide is also known as a dual GLP-1/GIP receptor agonist. These are both hormones that your system releases after you eat
Start your intake How a Bioverse monthly price is assembled In the compounded-telehealth model Bioverse uses, a monthly charge is rarely a single number
